# US 10,370,714 B2 · Th-17 differentiation markers for rosacea and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,714 B2
- Document ID: US10370714B2
- Status: Granted
- Kind: B2
- Application number: 14/129,679
- Filed: 2012-06-25
- Published: 2014-08-07
- Granted: 2019-08-06
- Earliest claimed: 2011-06-27
- Assignees: Galderma Research & Development; Universitat Munster
- Applicants: Martin Steinhoff
- Inventors: Martin Steinhoff
- Web page: https://patentgrep.com/patent/US10370714B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.

## Claims

### Claim 1

A method of detecting a level of gene expression of a marker for rosacea subtype I, subtype II, or subtype III in a patient, the method comprising:
(a) obtaining a skin sample from a patient suspected of having rosacea subtype I, subtype II, or subtype III;
(b) measuring gene expression of IL 26, and/or CCL20 in the skin sample;
(c) comparing the gene expression of IL 26, and/or CCL20 in the skin sample against a level of gene expression of IL 26, and/or CCL20 in a control skin sample of a healthy individual.

### Claim 2

A method for monitoring efficacy of a treatment intended for treating rosacea subtype I, subtype II, or subtype III, the method comprising:
(a) administering a desired treatment to an individual identified as having one or more symptoms of rosacea subtype I, subtype II, or subtype III,
(b) taking skin samples from the individual before, during, and/or after the administration,
(c) comparing gene expression of IL-26, and/or CCL20, in the skin samples.

### Claim 3 (depends on 1)

The method of claim 1, wherein the skin sample is from a biopsy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the skin sample from the patient is from a patient suspected of having rosacea subtype I or subtype II.

### Claim 5 (depends on 1)

The method of claim 1, wherein the expression in the patient is at least 50% more than the expression in the control sample.

### Claim 6 (depends on 5)

The method of claim 5, wherein the expression in the patient is at least 100% more than the expression in the control sample.

### Claim 7 (depends on 5)

The method of claim 5, wherein the expression in the patient is at least 200% more than the expression in the control sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein (b) further comprises measuring gene expression of IL-6, IL-17A, IL-17F, IL-22, and/or TNF alpha, in the skin sample; and (c) further comprising comparing the gene expression of IL-6, IL-17A, IL-17F, IL-22, and/or TNF alpha, in the skin sample against a level of expression of IL-6, IL-17A, IL-17F, IL-22, and/or TNF alpha in a control skin sample of a healthy individual.

### Claim 9 (depends on 8)

The method of claim 8, wherein the skin sample from the patient is from a patient suspected of having rosacea subtype II.

### Claim 10 (depends on 1)

The method of claim 1, wherein (b) further comprises measuring gene expression of IL-17A in the skin sample; and (c) further comprising comparing the gene expression of IL-17A in the skin sample against a level of expression of IL-17A in a control skin sample of a healthy individual.

### Claim 11 (depends on 10)

The method of claim 10, wherein the skin sample from the patient is from a patient suspected of having rosacea subtype III.